Skip to content
Catalyst

resveratrolFinding

Resveratrol has no detected effect on waist-to-hip ratio

no difference foundModerate evidenceFinding

01 · The sentence it was drawn from

“The result indicated that there was just the trend of decrease but no significance after treatment with resveratrol compared with placebo in BW [SMD = − 0.08, 95% CI (−0.35, 0.18), p = 0.544], BMI [SMD = − 0.07, 95% CI (−0.33, 0.20), p = 0.633], WC [SMD = −0.73, 95% CI (−1.97, 0.51), p = 0.249] and WHR [SMD = −0.12, 95% CI (−0.40, 0.16), p = 0.405] (Supplementary Figures S14, 15).”
Quoted verbatim from Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.
This finding among the 11 findings on its endpoint

resveratrol

Waist-to-hip ratio

no difference found

Effect as reported

−0.12standardised mean difference

CI −0.4 to 0.16

Who
adults with NAFLD, resveratrol vs placebo, 5 pooled clinical RCTs
Dose studied
300-3,000 mg/day, 8-24 weeks, pooled across trials

Moderate evidencePMID 37767399 · 2023

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M3RM673HB5PNE67Z9BKBCJFH